Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycomimetic 153
- Development stage
- Preclinical
- Lead developer
- University of Wisconsin–Madison
- Modality
- Small Molecules, Peptides
01
Overview
Glycomimetic 153 is a synthetic glycomimetic ligand designed to target and block the Siglec-9 receptor, an inhibitory checkpoint on immune cells such as Natural Killer (NK) cells. Siglec-9 typically binds to sialic acid-containing glycans, such as those found on the mucin MUC16, which is overexpressed in ovarian cancer cells. By blocking this interaction, glycomimetic 153 prevents the inhibitory signaling that allows cancer cells to evade the immune system, thereby enhancing the cytolytic activity and recognition of tumor cells by NK cells. Developed by researchers at the University of Wisconsin-Madison, it is being investigated for its potential to augment antitumor immunity in epithelial ovarian cancer.
02
Targets
SIGLEC9 (Sialic acid-binding immunoglobulin-like lectin 9)
Beyond the preview
Go deeper on glycomimetic 153.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycomimetic 153.